Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC)

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 3, 2015, Pages 689-698

  Lokhov, Petr G ^a,b   Balashova, Elena E ^a,b  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b ZAO BioBohemia   (Russian Federation)

Author keywords

Antiangiogenic cancer vaccine; Cell heterogeneity; Cell proteomic footprinting; Cell surface antigens; Cell surface profiling; Microvascular endothelial cells; Universal cancer vaccine; Vaccine design

Indexed keywords

CANCER VACCINE; MEMBRANE ANTIGEN; TUMOR ANTIGEN; MEMBRANE PROTEIN;

AUTOIMMUNITY; CANCER IMMUNIZATION; CAPILLARY ENDOTHELIAL CELL; CELL DAMAGE; CELL PROLIFERATION; CELL SURFACE; CHEMICAL COMPOSITION; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; NONHUMAN; NOTE; PHENOTYPE; PROTEOMICS; VACCINE PRODUCTION; ENDOTHELIUM CELL; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROVASCULATURE; NEOPLASMS;

ANTIGENS, NEOPLASM; CANCER VACCINES; ENDOTHELIAL CELLS; HUMANS; MEMBRANE PROTEINS; MICROVESSELS; NEOPLASMS;

EID: 84928673295     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1011022     Document Type: Note

References (90)

1. Lollini P-L, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006; 6:204-16; PMID:16498443; http://dx.doi.org/10.1038/nrc1815.
2. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012; 104:599-613; PMID:22395641; http://dx.doi.org/10.1093/jnci/djs033.
3. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390:404-7; PMID:9389480; http://dx.doi.org/10.1038/37126.
4. Bussolino F, Arese M, Audero E, Giraudo E, Marchió S, Mitola S, Primo L, Serini G. Aspects of Tumor Angiogenesis. In: Preziosi L, editor. Cancer Modelling and Simulation. London: Chapman and Hall/CRC; 2003. page 1-22.
5. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285:1182-6; PMID:4938153; http://dx.doi.org/10.1056/NEJM197108122850711.
6. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6; PMID:1688381; http://dx.doi.org/10.1093/jnci/82.1.4.
7. Pluda JM. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997; 24:203-18; PMID:9129690.
8. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57; PMID:11001068; http://dx.doi.org/10.1038/35025220.
9. Copier J, Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol 2006; 25:297-319; PMID:17169778; http://dx.doi.org/10.1080/08830180600992472.
10. Old LJ. Cancer vaccines: an overview. Cancer Immun a J Acad Cancer Immunol 2008; 8 Suppl 1:1.
11. Chiang CLL, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010; 22:132-43.
12. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ, Huang MJ, Lou YY, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6:1160-6; PMID:11017149; http://dx.doi.org/10.1038/80506.
13. Corsini E, Gelati M, Calatozzolo C, Alessandri G, Frigerio S, De Francesco M, Poiesi C, Parati E, Croci D, Boiardi A, et al. Immunotherapy with bovine aortic endothelial cells in subcutaneous and intracerebral glioma models in rats: Effects on survival time, tumor growth, and tumor neovascularization. Cancer Immunol Immunother 2004; 53:955-62; PMID:15449042; http://dx.doi.org/10.1007/s00262-004-0529-5.
14. Okaji Y, Tsuno NH, Kitayama J, Saito S, Takahashi T, Kawai K, Yazawa K, Asakage M, Hori N, Watanabe T, et al. Vaccination with autologous endothelium inhibits angiogenesis and metastasis of colon cancer through autoimmunity. Cancer Sci 2004; 95:85-90; PMID:14720332; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03175.x.
15. Chen X-Y, Zhang W, Zhang W, Wu S, Bi F, Su Y-J, Tan X-Y, Liu J-N, Zhang J. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity. Clin Cancer Res 2006; 12:5834-40; PMID:17020991; http://dx.doi.org/10.1158/1078-0432.CCR-06-1105.
16. Okaji Y, Tsuno NH, Saito S, Yoneyama S, Tanaka M, Nagawa H, Takahashi K. Vaccines targeting tumour angiogenesis-a novel strategy for cancer immunotherapy. Eur J Surg Oncol 2006; 32:363-70.
17. Scappaticci FA, Nolan GP. Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine. Anticancer Res 2003; 23:1165-72; PMID:12820367.
18. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191:795-804; PMID:10704461; http://dx.doi.org/10.1084/jem.191.5.795.
19. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298:850-4; PMID:12242449.
20. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372-7; PMID:12826605.
21. Maker A V, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12:1005-16; PMID:16283570.
22. Attia P, Phan GQ, Maker A V, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen- 4. J Clin Oncol 2005; 23:6043-53; PMID:16087944.
23. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3:630-41; PMID:12974478; http://dx.doi.org/10.1038/nri1150.
24. Hart MN, Sadewasser KL, Cancilla PA, DeBault LE. Experimental autoimmune type of vasculitis resulting from activation of mouse lymphocytes to cultured endothelium. Lab Invest 1983; 48:419-27; PMID:6834786.
25. Matsuda M. Experimental glomerular tissue injury induced by immunization with cultured endothelial cell plasma membrane. Acta Pathol Jpn 1988; 38:823-39; PMID:3055806.
26. Aird WC. Phenotypic heterogeneity of the endothelium: I. Ssructure, function, and mechanisms. Circ Res 2007; 100:158-73; PMID:17272818; http://dx.doi.org/10.1161/01.RES.0000255691.76142.4a.
27. Aird WC. Phenotypic heterogeneity of the endothelium: II. representative vascular beds. Circ Res 2007; 100:174-90; PMID:17272819; http://dx.doi.org/10.1161/01.RES.0000255690.03436.ae.
28. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, et al. Genes expressed in human tumor endothelium. Science 2000; 289:1197-202; PMID:10947988; http://dx.doi.org/10.1126/science.289.5482.1197.
29. Khodarev NN, Yu J, Labay E, Darga T, Brown CK, Mauceri HJ, Yassari R, Gupta N, Weichselbaum RR. Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 2003; 116:1013-22; PMID:12584245; http://dx.doi.org/10.1242/jcs.00281.
30. Bhati R, Patterson C, Livasy CA, Fan C, Ketelsen D, Hu Z, Reynolds E, Tanner C, Moore DT, Gabrielli F, et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol 2008; 172:1381-90; PMID:18403594; http://dx.doi.org/10.2353/ajpath.2008.070988.
31. Hellebrekers DMEI, Castermans K, Viré E, Dings RPM, Hoebers NTH, Mayo KH, Oude Egbrink MGA, Molema G, Fuks F, van Engeland M, et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 2006; 66:10770-7; PMID:17108113; http://dx.doi.org/10.1158/0008-5472.CAN-06-1609.
32. Hellebrekers DMEI, Jair K-W, Viré E, Eguchi S, Hoebers NTH, Fraga MF, Esteller M, Fuks F, Baylin SB, van Engeland M, et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol Cancer Ther 2006; 5:467- 75; PMID:16505122; http://dx.doi.org/10.1158/1535-7163.MCT-05-0417.
33. Hellebrekers DMEI, Melotte V, Viré E, Langenkamp E, Molema G, Fuks F, Herman JG, Van Criekinge W, Griffioen AW, van Engeland M. Identification of epigenetically silenced genes in tumor endothelial cells. Cancer Res 2007; 67:4138-48; PMID:17483324; http://dx.doi.org/10.1158/0008-5472.CAN-06-3032.
34. Unger RE, Oltrogge JB, von Briesen H, Engelhardt B, Woelki U, Schlote W, Lorenz R, Bratzke H, Kirkpatrick CJ. Isolation and molecular characterization of brain microvascular endothelial cells from human brain tumors. In Vitro Cell Dev Biol Anim 2002; 38:273-81; PMID:12418924; http://dx.doi.org/10.1290/1071-2690(2002)038<0273:IAMCOB>2.0.CO;2.
35. Bussolati B, Deambrosis I, Russo S, Deregibus MC, Camussi G. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003; 17:1159-61; PMID:12709414.
36. Maciag T, Cerundolo J, Ilsley S, Kelley PR, Forand R. An endothelial cell growth factor from bovine hypothalamus: identification and partial characterization. Proc Natl Acad Sci U S A 1979; 76:5674-8; PMID:293671; http://dx.doi.org/10.1073/pnas.76.11.5674.
37. Lokhov PG, Balashova EE. Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro. Hum Vaccin Immunother 2013; 9:198-209; PMID:23442592; http://dx.doi.org/10.4161/hv.22828.
38. Balashova EE, Lokhov PG. Proteolytically-cleaved fragments of cell surface proteins stimulate a cytotoxic immune response against tumor-activated endothelial cells in vitro. J Cancer Sci Ther 2010; 2:126-131; http://dx.doi.org/10.4172/1948-5956.1000037.
39. Lokhov PG, Balashova EE. Universal cancer vaccine: an update on the design of cancer vaccines generated from endothelial cells. Hum Vaccin Immunother 2013; 9:1549-52; PMID:23571178; http://dx.doi.org/10.4161/hv.24300.
40. Lokhov PG, Balashova EE. Cellular cancer vaccines: an update on the development of vaccines generated from cell surface antigens. J Cancer 2010; 1:230-41; PMID:21151581; http://dx.doi.org/10.7150/jca.1.230.
41. Lokhov P, Balashova E, Dashtiev M. Cell proteomic footprint. Rapid Commun Mass Spectrom 2009; 23:680-2; PMID:19184978; http://dx.doi.org/10.1002/rcm.3928.
42. Thompson PL, Dessureault S. Tumor cell Vaccines. In: Shurin MR, Smolkin YS, editors. Immune-Mediated Diseases From Theory to Therapy. New York: Springer; 2007. page 345-55.
43. De Gruijl TD, Van Den Eertwegh AJM, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: From autologous to allogeneic tumor- And dendritic cell-based vaccines. Cancer Immunology, Immunotherapy. 2008; 57:1569-77.
44. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737.
45. Lang JM, Andrei AC, McNeel DG. Prioritization of cancer antigens: keeping the target in sight. Expert Rev Vaccines 2009; 8:1657-61; PMID:19943761; http://dx.doi.org/10.1586/erv.09.134.
46. Balashova EE, Lokhov PG. Proteolytically-cleaved fragments of cell-surface proteins from live tumor cells stimulate anti-tumor immune response in vitro. J Carcinog Mutagen 2010; 1:103; http://dx.doi.org/10.4172/2157-2518.1000103.
47. Balashova EE, Dashtiev MI, Lokhov PG. Proteomic Footprinting of Drug-Treated Cancer Cells as a Measure of Cellular Vaccine Efficacy for the Prevention of Cancer Recurrence. Mol Cell Proteomics 2012; 11: M111.014480-M111.014480; PMID:22074704; http://dx.doi.org/10.1074/mcp.M111.014480.
48. Kumar S, West DC, Ager A. Heterogeneity in endothelial cells from large vessels and microvessels. Differentiation 1987; 36:57-70; PMID:2451631; http://dx.doi.org/10.1111/j.1432-0436.1987.tb00181.x.
49. Lang I, Pabst MA, Hiden U, Blaschitz A, Dohr G, Hahn T, Desoye G. Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells. Eur J Cell Biol 2003; 82:163-73; PMID:12751902; http://dx.doi.org/10.1078/0171-9335-00306.
50. Shreeniwas R, Ogawa S, Cozzolino F, Torcia G, Braunstein N, Butura C, Brett J, Lieberman HB, Furie MB, Joseph-Silverstein J. Macrovascular and microvascular endothelium during long-term hypoxia: alterations in cell growth, monolayer permeability, and cell surface coagulant properties. J Cell Physiol 1991; 146:8-17; PMID:1990021; http://dx.doi.org/10.1002/jcp.1041460103.
51. Hewett PW. Identification of tumour-induced changes in endothelial cell surface protein expression: an in vitro model. Int J Biochem Cell Biol 2001; 33:325-35; PMID:11312103; http://dx.doi.org/10.1016/S1357-2725(01)00020-6.
52. Swerlick RA, Lee KH, Wick TM, Lawley TJ. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 1992; 148:78-83; PMID:1370173.
53. Swerlick RA, Lee KH, Li LJ, Sepp NT, Caughman SW, Lawley TJ. Regulation of vascular cell adhesion molecule 1 on human dermal microvascular endothelial cells. J Immunol 1992; 149:698-705; PMID:1378077.
54. Lee KH, Lawley TJ, Xu YL, Swerlick RA. VCAM-1-, ELAM-1-, and ICAM-1-independent adhesion of melanoma cells to cultured human dermal microvascular endothelial cells. J Invest Dermatol 1992; 98:79-85; PMID:1370233; http://dx.doi.org/10.1111/1523-1747.ep12495643.
55. Takeichi N, Economou GC, Boone CW. Accelerated regeneration of trypsin-treated surface antigens of simian virus 40-transformed BALB/3T3 cells induced by X-irradiation. Cancer Res 1976; 36:1258-62; PMID:177205.
56. Glick MC, Kimhi Y, Littauer UZ. Glycopeptides from surface membranes of neuroblastoma cells. Proc Natl Acad Sci U S A 1973; 70:1682-7; PMID:4515927; http://dx.doi.org/10.1073/pnas.70.6.1682.
57. Anglhileri LJ, Dermietzel. Cell coat in tumor cells- effects of trypsin and EDTA: a biochemical and morphological study. Oncology 1976; 33:17-23; PMID:185564; http://dx.doi.org/10.1159/000225095.
58. Baumann H, Doyle D. Effect of trypsin on the cell surface proteins of hepatoma tissue culture cells. Characterization of a carbohydrate-rich glycopeptide released from a calcium binding membrane glycoprotein. J Biol Chem 1979; 254:3935-46; PMID:438168.
59. Weiss L. The effects of trypsin on the size, viability and dry mass of sarcoma 37 cells. Exp Cell Res 1958; 14:80-3; PMID:13512305; http://dx.doi.org/10.1016/0014-4827(58)90214-3.
60. Barnard PJ, Weiss L, Ratcliffe T. Changes in the surface properties of embryonic chick neural retina cells after dissociation. Exp Cell Res 1969; 54:293-301; PMID:4975920; http://dx.doi.org/10.1016/0014-4827(69)90205-5.
61. Kraemer PM. Regeneration of sialic acid on the surface of Chinese hamster cells in culture. I. General characteristics of the replacement process. J Cell Physiol 1966; 68:85-90; PMID:5967192; http://dx.doi.org/10.1002/jcp.1040680112.
62. Kraemer PM. Sialic acid of mammalian cell lines. J Cell Physiol 1966; 67:23-34; PMID:5327858; http://dx.doi.org/10.1002/jcp.1040670104.
63. Kemp RB, Jones BM, Cunningham I, James MC. Quantitative investigation on the effect of puromycin on the aggregation of trypsin- And versene-dissociated chick fibroblast cells. J Cell Sci 1967; 2:323-40; PMID:4293085.
64. Pitelka DR, Kerkof PR, Gagne HT, Smith S, Abraham S. Characteristics of cells dissociated from mouse mammary glands. I. Method of separation and morphology of parenchymal cells from lactating glands.
65. De Luca C. The use of trypsin for the determination of cellular viability. Exp Cell Res 1965; 40:186-8; PMID:5891332; http://dx.doi.org/10.1016/0014-4827(65)90312-5.
66. Kraemer PM. Regeneration of sialic acid on the surface of Chinese hamster cells in culture. II. Incorporation of radioactivity from glucosamine-1-14C. J Cell Physiol 1967; 69:199-207; PMID:6033950; http://dx.doi.org/10.1002/jcp.1040690210.
67. Allen A, Snow C. The effect of trypsin or ethylenediaminetetraacetate on the surface of cells in tissue culture. Biochem J 1970; 117:32 P; PMID:4986872.
68. Snow C, Allen A. The release of radioactive nucleic acids and mucoproteins by trypsin and ethylenediaminetetra- Acetate treatment of baby-hamster cells in tissue culture. Biochem J 1970; 119:707-14; PMID:4992781.
69. Buck CA, Glick MC, Warren L. A comparative study of glycoproteins from the surface of control and Rous sarcoma virus transformed hamster cells. Biochemistry 1970; 9:4567-76; PMID:4319754; http://dx.doi.org/10.1021/bi00825a016.
70. Vestling MM, Murphy CM, Fenselau C. Recognition of trypsin autolysis products by high-performance liquid chromatography and mass spectrometry. Anal Chem 1990; 62:2391-4; PMID:2291484; http://dx.doi.org/10.1021/ac00220a025.
71. Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, Zhao R, Puravs E, Tra J, Michael CW, et al. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J Biol Chem 2003; 278:7607-16; PMID:12493773; http://dx.doi.org/10.1074/jbc.M210455200.
72. Jang JH, Hanash S. Profiling of the cell surface proteome. Proteomics 2003; 3:1947-54; PMID:14625857; http://dx.doi.org/10.1002/pmic.200300563.
73. Rodríguez-Ortega MJ, Norais N, Bensi G, Liberatori S, Capo S, Mora M, Scarselli M, Doro F, Ferrari G, Garaguso I, et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006; 24:191-7; http://dx.doi.org/10.1038/nbt1179.
74. Lund R, Leth-Larsen R, Jensen ON, Ditzel HJ. Efficient isolation and quantitative proteomic analysis of cancer cell plasma membrane proteins for identification of metastasis-associated cell surface markers. J Proteome Res 2009; 8:3078-90; PMID:19341246; http://dx.doi.org/10.1021/pr801091k.
75. Garcia J, Faca V, Jarzembowski J, Zhang Q, Park J, Hanash S. Comprehensive profiling of the cell surface proteome of Sy5Y neuroblastoma cells yields a subset of proteins associated with tumor differentiation. J Proteome Res 2009; 8:3791-6; PMID:19505085; http://dx.doi.org/10.1021/pr800964v.
76. Van Der Pol L, Tramper J. Shear sensitivity of animal cells from a culture-medium perspective. Trends Biotechnol. 1998; 16:323-8; PMID:9720320; http://dx.doi.org/10.1016/S0167-7799(98)01209-8.
77. Lau JY, Tchao R. Stressed polystyrene causes increased membrane sensitivity of adherent cells to fluid shear force: Technical note. Eur Cell Mater 2007; 14:40-43; discussion 43-44; PMID:17828704.
78. McQueen A, Bailey JE. Influence of serum level, cell line, flow type and viscosity on flow-induced lysis of suspended mammalian cells. Biotechnol Lett 1989; 11:531-536; http://dx.doi.org/10.1007/BF01040030.
79. McQueen A, Meilhoc E, Bailey JE. Flow effects on the viability and lysis of suspended mammalian cells. Biotechnol Lett 1987; 9:831-6; http://dx.doi.org/10.1007/BF01026191.
80. Tchao R. Fluid shear force and turbulence-induced cell death in plastic tissue culture flasks. In Vitro Toxicol 1996; 9:93-100.
81. Kyte JA. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs 2009; 18:687- 94; PMID:19388882; http://dx.doi.org/10.1517/13543780902897631.
82. Shaw VE, Naisbitt DJ, Costello E, Greenhalf W, Park BK, Neoptolemos JP, Middleton GW. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Rev Vaccines 2010; 9:1007-16; PMID:20822343; http://dx.doi.org/10.1586/erv.10.92.
83. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN, Wilson D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990; 265:15286-93; PMID:1697589.
84. Gendler SJ. MUC1, The renaissance molecule. J Mammary Gland Biol Neoplasia 2001; 6:339-53; PMID:11547902; http://dx.doi.org/10.1023/A:1011379725811.
85. Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther 2007; 6:481-6; PMID:18027437; http://dx.doi.org/10.4161/cbt.6.4.4201.
86. McCarthy N. Running a MUC1. Nat Rev Cancer 2012; 12:317-317; PMID:22495322.
87. Paczesny S, Shi H, Saito H, Mannoni P, Fay J, Banchereau J, Palucka AK. Measuring melanoma-specific cytotoxic T lymphocytes elicited by dendritic cell vaccines with a tumor inhibition assay in vitro. J Immunother 2005; 28:148-57; PMID:15725959; http://dx.doi.org/10.1097/01.cji.0000154247.97254.ef.
88. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16- induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18:86-94; PMID:8574470; http://dx.doi.org/10.1097/00002371-199508000-00002.
89. Kern PA, Knedler A, Eckel RH. Isolation and culture of microvascular endothelium from human adipose tissue. J Clin Invest 1983; 71:1822-9; PMID:6306056; http://dx.doi.org/10.1172/JCI110937.
90. Correa de Sampaio P, Auslaender D, Krubasik D, Failla AV, Skepper JN, Murphy G, English WR. A heterogeneous in vitro three dimensional model of tumourstroma interactions regulating sprouting angiogenesis. PLoS One 2012; 7; PMID:22363483; http//dx.doi.org/10.1371/journal.pone.0030753.